SEPSIS Alert Test

Lead Participant: MOLOGIC LTD.

Abstract

Sepsis is one of the most common deadly diseases and one of the leading causes of death in the developed world exerting a huge human and economic toll. In the UK there are over 100,000 cases and 37,000 deaths annually. Rapid diagnosis is critical to the effective treatment of the patient and offers the prospect of reduced mortality but existing diagnostic tools lack the sensitivity and/or specificity needed for effective stratification of sepsis to enable early, effective treatment. Mologic is developing an easy-to-use, 10 minute lateral flow based assay that can be used in hospital A&E, wards and intensive care units by bedside nurses to provide rapid discrimination of sepsis. This will enable faster treatment, stratification of patients by degree of risk into appropriate care areas, and financial savings in hospital systems by both reducing complications and overtreatment. The single use cartridges will be compatible with a sample of whole blood which could be obtained from a fingerprick or a venous blood sample.

Lead Participant

Project Cost

Grant Offer

MOLOGIC LTD. £1,255,191 £ 878,634
 

Participant

INNOVATE UK

Publications

10 25 50